Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

SupiraMedical-FDA

More Like This

PR Newswire associated0

Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States

PR Newswire associated0

PulseCath Achieves MDR CE Certification for iVAC 2L, Paving the Way for Complex High-Risk Percutaneous Coronary Interventions

Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt

PR Newswire associated0

Heart Failure start-up, Acorai, closes oversubscribed $4m funding round

PR Newswire associated0

Heart Failure start-up, Acorai, secures €2.3m grant funding from the European Commission

PR Newswire associated0

Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial

Corvia's RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data

PR Newswire associated0

CardiaCare Completes Seed Extension Raise to Support Clinical Pilot Studies